RBM39
Function
RNA-binding protein that acts as a pre-mRNA splicing factor (PubMed:15694343, PubMed:24795046, PubMed:28302793, PubMed:28437394, PubMed:31271494). Acts by promoting exon inclusion via regulation of exon cassette splicing (PubMed:31271494). Also acts as a transcriptional coactivator for steroid nuclear receptors ESR1/ER-alpha and ESR2/ER-beta, and JUN/AP-1, independently of the pre-mRNA splicing factor activity (By similarity).
Post-translational modifications
Aryl sulfonamide anticancer drugs, such as indisulam (E7070) or E7820, promote ubiquitination and subsequent degradation by the DCX(DCAF15) complex (PubMed:28302793, PubMed:28437394, PubMed:31693891). RBM39 degradation results in splicing defects and death in cancer cell lines (PubMed:28302793, PubMed:28437394, PubMed:31693891). Aryl sulfonamide anticancer drugs change the substrate specificity of DCAF15 by acting as a molecular glue that promotes binding between DCAF15 and weak affinity interactor RBM39 (PubMed:31686031, PubMed:31819272).
Sequence Similarities
Belongs to the splicing factor SR family.
Tissue Specificity
Widely expressed. Highly expressed in pancreas, skeletal muscle, lung and brain (PubMed:8227358). Expressed at intermediate level in kidney, liver and heart (PubMed:8227358).
Cellular localization
- Nucleus speckle
- Concentrated in nuclear speckles (PubMed:8227358). Colocalizes with the core spliceosomal snRNP proteins (PubMed:8227358).
Alternative names
HCC1, RNPC2, RBM39, RNA-binding protein 39, CAPER alpha, Hepatocellular carcinoma protein 1, RNA-binding motif protein 39, RNA-binding region-containing protein 2, Splicing factor HCC1, CAPERalpha